Investigation into the mechanism of action of the Yiqi Rougan Jiedu formula in the treatment of liver cancer based on network pharmacology and experi-mental validation
Objective:To explore the molecular mechanisms of Yiqi Rougan Jiedu formula in treating hepatocellular carcinoma(HCC)based on network pharmacology and experimental validation.Methods:Potential targets and signaling pathways regulated by the herbal formula for HCC were obtained through network pharmacology.A mouse model with H22 hepatocellular carcinoma cell subcutaneous transplantation tumor was established for animal experiments.Different doses of yiqi Rougan Jiedu formula were administered,and the growth of tumor tissues,HE staining of mouse tumor tissues,and WB detection of PI3K/AKT/NFκB signaling pathway protein expression in tumor tissues were evaluated.Results:Network pharmacology showed that 64 active compounds were identified,with 236 potential targets intersecting disease targets,including 24 core targets.yiqi Rougan Jiedu formula may affect common mutated genes in liver cancer such as TP53,ALB,PTEN,CCND1;regulate Th1,Th2,Th17 cell differentiation,downregulate PD-1 checkpoint and PD-L1 expression,as well as block key signaling pathways such as PI3K/AKT and NFκB to exert anti-tumor effects.Experimental results indicated that compared to the model group,yiqi Rougan Jiedu formula could inhibit tumor volume growth in mice carrying tumors and significantly reduce expression of proteins in the PI3K/AKT/NFκB pathway.Conclusion:yiqi Rougan Jiedu formula may play a role in treating HCC through multiple components,multiple targets,and multiple pathways by potentially affecting the PI3K/AKT/NFκB signaling pathway to inhibit liver cancer development.
万方数据
维普
